COGT (COGT) Stock Analysis
Verdict: HOLD
FDA NDA acceptance for bezuclastinib validates late-stage pipeline, but a $266M annual FCF burn limits cash runway to ~14 months.
Investment score: 47/100
The model maintains a HOLD evaluation on Cogent Biosciences Inc (COGT). FDA NDA acceptance for bezuclastinib provides key catalyst visibility, but substantial cash burn ($266.00M USD in 2025) and a $5.65B USD market capitalization constrain near-term risk-adjusted expansion.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| MIRM | -6.69 | -592.09 | 9.61 | -8.20 | — | -1.39 |
| ORKA | -37.87 | 5.28 | 0.00 | -37.95 | — | 0.00 |
| SRRK | -14.92 | 25.41 | 0.00 | -14.33 | — | 0.00 |
| TVTX | -141.07 | 241.99 | 9.98 | 4146.61 | — | -0.07 |
| DNTH | -788.38 | 4.90 | 3010.88 | -190.56 | — | -15.71 |